ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_5/article-pS-1.xmlPreliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/Suppl_5/article-pS-1.pdf2026-04-18Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p874.xmlNew Virus Associated With Merkel Cell Carcinoma Development2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p874.pdf2026-04-18New Virus Associated With Merkel Cell Carcinoma Developmenthttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p867.xmlIndoor Ultraviolet Tanning: What the Data Do and Do Not Show Regarding Risk of Melanoma and Keratinocyte Malignancies2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p867.pdf2026-04-18Indoor Ultraviolet Tanning: What the Data Do and Do Not Show Regarding Risk of Melanoma and Keratinocyte Malignancieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p881.xmlUsing Imatinib as Neoadjuvant Therapy in Dermatofibrosarcoma Protuberans: Potential Pluses and Minuses2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p881.pdf2026-04-18Using Imatinib as Neoadjuvant Therapy in Dermatofibrosarcoma Protuberans: Potential Pluses and Minuseshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p833.xmlAvastin, ODAC, and the FDA: Are We Drafting the Right Players?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p833.pdf2026-04-18Avastin, ODAC, and the FDA: Are We Drafting the Right Players?https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-pxi.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-pxi.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p836.xmlBasal Cell and Squamous Cell Skin Cancers2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p836.pdf2026-04-18Basal Cell and Squamous Cell Skin Cancershttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p888.xmlThe Economic Impact of Non-Melanoma Skin Cancer: A Review2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p888.pdf2026-04-18The Economic Impact of Non-Melanoma Skin Cancer: A Reviewhttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p958.xmlCancer-Related Fatigue: Definitions and Clinical Subtypes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p958.pdf2026-04-18Cancer-Related Fatigue: Definitions and Clinical Subtypeshttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p904.xmlCancer-Related Fatigue2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p904.pdf2026-04-18Cancer-Related Fatiguehttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p933.xmlPsychostimulants for Cancer-Related Fatigue2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p933.pdf2026-04-18Psychostimulants for Cancer-Related Fatiguehttps://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p945.xmlExercise Programs for Cancer-Related Fatigue: Evidence and Clinical Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/8/8/article-p945.pdf2026-04-18Exercise Programs for Cancer-Related Fatigue: Evidence and Clinical Guidelines